<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04554589</url>
  </required_header>
  <id_info>
    <org_study_id>0000-0002-141</org_study_id>
    <nct_id>NCT04554589</nct_id>
  </id_info>
  <brief_title>The Off Label Use of Glycopyrrolate in the Adults Intensive Care Unit.</brief_title>
  <official_title>The Off Label Use of Glycopyrrolate in the Adults Intensive Care Unit.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tracheostomized patients in the ICU can have excessive tracheal secretions due to various&#xD;
      causes as hyperactive airway, irritation of the mucus producing cells and inhibition of the&#xD;
      ciliary functions. Excessive secretions will necessitate frequent suctions which carries the&#xD;
      risk of tracheostomy tube obstruction if not managed properly. Excessive tracheal secretions&#xD;
      may prolong the ICU stay, increase the nurses workload and increase patients morbidity and&#xD;
      mortality.&#xD;
&#xD;
      This clinical trial hypothesizes that the use of glycopyrrolate may decrease the tracheal&#xD;
      secretions and hence avoid such complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients fulfilling the inclusion criteria will be randomly assigned into one of 2 groups:&#xD;
&#xD;
      Group G (Intervention group): Patients will receive Glycopyrrolate 0.2 mg IV every 8 hours.&#xD;
&#xD;
      Group C (Control group): Patients will receive 2 mL Normal saline every 8 hours.&#xD;
&#xD;
      Both injections will be labelled as drug A and drug B in the satellite pharmacy .&#xD;
&#xD;
      Both the attending physician, nurse and data collector will be blinded to the injection&#xD;
      given.&#xD;
&#xD;
      Measurements data will be collected and recorded daily in the pre-prepared CRF during the&#xD;
      study period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 14, 2020</start_date>
  <completion_date type="Anticipated">April 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of suctions per day</measure>
    <time_frame>6 days</time_frame>
    <description>Number of suctions per day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The duration of ICU days</measure>
    <time_frame>90 days</time_frame>
    <description>the total days the patient will spend in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fio2</measure>
    <time_frame>6 days</time_frame>
    <description>Fio2 on mechanical ventilation every 4 hours daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean airway pressure</measure>
    <time_frame>6 days</time_frame>
    <description>Mean airway pressure will be recorded every 4 hours on the mechanical ventilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive end expiatory pressure PEEP</measure>
    <time_frame>6 days</time_frame>
    <description>PEEP will be recorded every 4 hours on the mechanical ventilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of mechanical ventilation days</measure>
    <time_frame>90 days</time_frame>
    <description>Total days spent on mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects of Glycopyrrolate</measure>
    <time_frame>6 days</time_frame>
    <description>Episodes of tachycardia if heart rate reach 120 beats / minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid intake</measure>
    <time_frame>6 days</time_frame>
    <description>Fluid balance calculated daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total leukocyte count</measure>
    <time_frame>6 days</time_frame>
    <description>Total leukocyte count daily</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Effect of Drugs</condition>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>receive Glycopyrrolate at dose of 0.2 mg IV every 8 hours daily .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>receive normal saline 2 ml IV every 8 hours daily .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate 0.2 MG</intervention_name>
    <description>injections</description>
    <arm_group_label>intervention group</arm_group_label>
    <other_name>Glycopyrronium Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>normal saline</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients above 18 years old.&#xD;
&#xD;
          2. Patients who are admitted to ICU for more than 72 hours.&#xD;
&#xD;
          3. Patients who have tracheostomy tubes with reported frequent need for suction of the&#xD;
             tracheostomy tube secretions more than once every 4 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have evidence of lower respiratory tract infections and have positive&#xD;
             cultures from the tracheal aspirate.&#xD;
&#xD;
          2. Patients who have known sensitivity to Glycopyrrolate.&#xD;
&#xD;
          3. Patients who have tachycardia (heart rate above 120 Beats/minute) or known to have&#xD;
             tachyarrhythmiase.g atrial fibrillation.&#xD;
&#xD;
          4. Patients with mitral stenosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed Abosamak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>health care provider</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammed Abosamak, MD</last_name>
    <phone>00966599056616</phone>
    <email>SAMAKAWY10@YAHOO.COM</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahmoud Fawzi, MD</last_name>
    <phone>00966561339935</phone>
    <email>mfawzi9966@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Security Forces Hospital</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <contact>
      <last_name>Mohammed Abosamak</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>September 20, 2020</last_update_submitted>
  <last_update_submitted_qc>September 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>MOHAMMED FAWZI ALI ABOSAMAK</investigator_full_name>
    <investigator_title>ICU consultant</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data sharing will be participated after clinical trial registration complete.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

